Proscia: Inside Access25: The Future of Precision Medicine Starts Now
From the Proscia blog:
At Access25, we brought together leaders from life sciences, diagnostics, and technology for a global virtual event dedicated to advancing precision medicine by starting where insight begins: the moment of diagnosis.
The goal was simple but ambitious. We wanted to bridge two worlds that have long operated in parallel: biopharma, where research teams design and deliver targeted therapies, and clinical laboratories, where pathologists generate the earliest and most complete signals of disease. Access25 was built to change that: to demonstrate how Proscia Aperture and the broader Concentriq ecosystem can finally connect diagnosis to discovery and make precision medicine accessible, scalable, and faster for everyone involved.
We began with an opening message from our CEO David West, filmed at the College of Physicians of Philadelphia, a symbolic setting where centuries of medical innovation remind us that progress comes from connecting ideas, disciplines, and people.
From there, the event unfolded in three parts:
- A Biopharma Track focused on discovery and real-time R&D.
- A Clinical Track highlighting how labs are shaping the future of precision medicine.
- A Partner Expo showcasing the collaborators powering this shared vision.
The Biopharma Track: Making Real-Time R&D a Reality
The biopharma sessions were designed for drug developers, translational scientists, and evidence-generation teams who know that speed and precision in R&D depend on timely, representative data. For this audience, Access25 introduced Aperture as a way to move beyond retrospective datasets and enable real-time insight at diagnosis.
Through a mix of discussion and live demos, we explored how Aperture helps biopharma teams turn diagnostic data into actionable intelligence. We were joined by industry thought leaders including Dr. Paul Mesange, Global Director of Operations at Labcorp, Ralph Riley, Director of Precision Medicine Access Strategy at Johnson & Johnson, and Dr. Suso Platero, Global Precision Medicine Leader, who provided critical context on the industry need for faster, more efficient evidence generation.
Participants saw how the platform identifies trial-eligible patients the moment pathology results are produced, tracks biomarker prevalence across diverse populations, and builds regulatory-grade evidence for drug approvals and label expansion. What once required months of manual curation now happens within minutes, empowering R&D teams to design smarter studies, accelerate enrollment, and reach the right patients while they are still eligible.
At the heart of this session was the Aperture Flywheel: a simple but powerful idea that every diagnosis fuels discovery, and every discovery feeds back to improve the next diagnosis. As labs digitize more slides through Concentriq and feed those data into Aperture, R&D teams gain earlier, richer insights into real-world disease. In turn, those insights lead to faster development cycles, more efficient trial design, and better access for patients. It’s a self-reinforcing loop of progress, one that turns the diagnostic process into a catalyst for innovation.
The session closed with a detailed demonstration of how Aperture operates inside a modern data environment. From an intuitive dashboard, users can create a study, define inclusion and exclusion criteria in natural language, and instantly query across multimodal datasets, including pathology images, AI-derived biomarkers, and clinical metadata. As new diagnoses are added, cohorts update automatically, ensuring that evidence generation never fall behind the pace of care.
The Clinical Track: Empowering the Modern Laboratory
While biopharma teams focused on discovery, the clinical track turned to the laboratories that make it all possible. Diagnostic labs sit at the foundation of healthcare, producing the pathology data that defines nearly every patient journey. Yet many face shrinking margins, workforce shortages, and increasing complexity. We built this track to show how digital pathology and Aperture together can elevate labs beyond those constraints, enabling them to participate directly in precision medicine while strengthening daily operations.
Through discussions led by experts from leading clinical institutions, including Dr. Bilal Ahmad (Pathologist, Spectrum Healthcare Partners), Dr. Derek Welch (President and Chief Medical Officer, PathGroup), and Dr. Monika Lamba Saini (Global Translational Pathology Leader, ADC Therapeutics), attendees learned how Concentriq serves as the digital backbone of diagnostic workflows, delivering scalability, collaboration, and AI readiness. From there, Aperture extends that infrastructure into the life sciences ecosystem, allowing labs to contribute de-identified data, connect eligible patients to ongoing studies, and create new revenue opportunities tied to research and companion diagnostics.
What resonated most was the idea that participation doesn’t require an overhaul of existing processes. Labs using Concentriq can activate Aperture without disrupting workflows or adding new systems. The platform integrates directly into existing infrastructure, enabling access to a broader precision medicine network with minimal friction. For laboratories, it represents both a strategic evolution and a tangible way to improve patient impact, helping them transition from service providers to scientific partners in the therapy development process.
Ultimately, the Clinical Track showed that the precision medicine flywheel is powered by the people closest to patients. Every slide scanned, every case diagnosed, and every insight shared helps build a global learning network, one that accelerates both innovation and access.
The Partner Expo: Powering a Connected Ecosystem
The final portion of Access25 celebrated the ecosystem that makes this vision possible. Our Partner Expo featured a world-class group of organizations building the technologies, infrastructure, and AI models that extend Proscia’s platform and amplify its impact.
Attendees explored virtual sessions and showcases from Amazon Web Services (AWS), Agilent Technologies, Siemens Healthineers, Ibex Medical Analytics, Visiopharm, Mindpeak, Bioptimus, Owkin, and Primaa. Each partner brought a unique perspective on how cloud computing, multimodal AI, and enterprise integration can strengthen digital pathology workflows and accelerate adoption at scale. The diversity of solutions demonstrated that precision medicine isn’t a single product, it’s an ecosystem of collaboration between technology leaders, pathologists, and data scientists working toward the same outcome: getting life-changing therapies to patients faster.
What Comes Next
If you missed Access25, you can still explore the full experience, including all sessions, demos, and partner showcases, by registering to view the content on demand here.
SOURCE: Proscia
